The impact of genital warts: Loss of quality of life and cost of treatment in eight sexual health clinics in the UK

Sexually Transmitted Infections

Volumn 87, Issue 6, 2011, Pages 458-463

  Woodhall, S C ^a,b   Jit, M ^b   Soldan, K ^b   Kinghorn, G ^c   Gilson, R ^d   Nathan, M ^e   Ross, J D ^f   Lacey, C J N ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^f Whittall Street Clinic ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EMLA; IMIQUIMOD; PODOPHYLLOTOXIN; TRICHLOROACETIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CARBON DIOXIDE LASER; CONDYLOMA ACUMINATUM; CROSS-SECTIONAL STUDY; CRYOTHERAPY; CURETTAGE; DIODE LASER; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCREENING; SEXUAL HEALTH; SEXUALLY TRANSMITTED DISEASE; TREATMENT DURATION; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; CONDYLOMATA ACUMINATA; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; VENEREOLOGY; YOUNG ADULT;

EID: 80052923242     PISSN: 13684973     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/sextrans-2011-050073     Document Type: Article

References (41)

1. Salisbury DM. (Not) warts and all. Government fully considered HPV vaccine. BMJ 2008;337:a2552.
2. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008;337:a769.
3. Munoz N, Bosch FX, De Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27. (Pubitemid 36159887)
4. Howell-Jones R, Bailey A, Beddows S, et al. Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br J Cancer 2010;103:209-16.
5. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493.
6. Brown DR, Schroeder JM, Bryan JT, et al. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999;37:3316-22. (Pubitemid 29455226)
7. Health Protection Agency STI Annual Data Tables. Table 2: Total number of STI diagnoses and other episodes of care seen at genitourinary medicine clinics, UK and England 2000-2009. http://www.hpa.org.uk/web/ HPAweb&HPAwebStandard/HPAweb-C/1203348026613 (accessed Aug 2010).
8. Woodhall SC, Lacey CJN, Wikstrom A, et al. European Guidelines (IUSTI/WHO) on the management of anogenital warts. Poster presentation at the 25th International Papillomavirus Conference; 8-14 May 2009. Malmö, Sweden, 2009.
9. Desai S, Wetten S, Woodhall SC, et al. Genital warts and cost of care in England. Sex Transm Infect 2011;87:464-8.
10. Choi YH, Jit M, Gay N, et al. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 2010;28:4091-102.
11. Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009;85:499-502.
12. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011;11:39-44.
13. Woodhall S, Ramsey T, Cai C, et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 2008;84:161-6. (Pubitemid 351871484)
14. Woodhall SC, Jit M, Cai C, et al. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom. Sex Transm Dis 2009;36:515-21.
15. Hammond P. (Not) warts and all. BMJ 2008;337:a2186.
16. O'Mahony C. Government decision on national human papillomavirus vaccine programme is a sad day for sexual health. Sex Transm Infect 2008;84:251.
17. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
18. Dolan P, Gudex C, Kind P, et al. The time trade-off method: results from a general population study. Health Econ 1996;5:141-54. (Pubitemid 126484860)
19. Kind P, Dolan P, Gudex C, et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998;316:736-41. (Pubitemid 28121072)
20. Curtis L. Unit costs of health and social care. 2009. http://www.pssru.ac.uk/uc/uc2009contents.htm (accessed Jul 2010).
21. NHS. NHS electronic drug tariff. http://www.ppa.org.uk/ppa/edt-intro.htm (accessed Aug 2010).
22. Joint Formulary Committee. British National Formulary. 59th edn. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2010.
23. Pearce V, Grant A, Adams E. Technical document - Phase 1 methodology of the proposed integrated sexual health pricing and currencies for London. Community Sexual Health Services. London: Pathway Analytics, 2009.
24. BASHH Standards for the Management of Sexually Transmitted Infections. London: British Association of Sexual Health and HIV, 2010. http://www.bashh. org/guidelines (accessed Aug 2010).
25. Mortensen GL. Long-term quality of life effects of genital warts - a follow-study. Dan Med Bull 2010;57:A4140.
26. Persson G, Dahlof LG, Krantz I. Physical and psychological effects of anogenital warts on female patients. Sex Transm Dis 1993;20:10-13. (Pubitemid 23082231)
27. Data from the GU Medicine Clinical Activity Dataset (GUMCAD). London: Health Protection Agency, 2010.
28. Myers E, Green S, Lipkus I. Patient preferences for health states related to HPV infection: visual analogue scales versus time trade-off elicitation. Proceedings of the 21st International Papillomavirus Conference; 20-27 Feb 2004, Mexico City, Mexico, 2004.
29. Brown RE, Breugelmans JG, Theodoratou D, et al. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006;22:663-70.
30. Marra C, Ogilvie G, Gastonguay L, et al. Patients with genital warts have a decreased quality of life. Sex Transm Dis 2009;36:258-60.
31. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-8. (Pubitemid 40271061)
32. Dee A, Howell F, O'Connor C, et al. Determining the cost of genital warts: a study from Ireland. Sex Transm Infect 2009;85:402-3.
33. Langley PC, White DJ, Drake SM. The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int J STD AIDS 2004;15:501-8. (Pubitemid 39120231)
34. Marra F, Ogilvie G, Colley L, et al. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect 2009;85:111-15.
35. Pirotta M, Stein AN, Conway EL, et al. Genital warts incidence and healthcare resource utilisation in Australia. Sex Transm Infect 2010;86:181-6.
36. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003;36:1397-403. (Pubitemid 36702873)
37. Monsonego J, Breugelmans JG, Bouee S, et al. [Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France]. Gynecol Obstet Fertil 2007;35:107-13 [in French].
38. Fiander A, Cohet C. for the PasQual Study Team. Psychosocial impact of HPV-related diseases in men in the UK: the PasQual study. Proceedings of Eurogin 2010 Conference; 17-20 Feb 2010, Monte Carlo, Monaco, 2010.
39. Fiander A, Cohet Cfor the PasQual Study Team. Psychosocial impact of HPV-related diseases in women in the UK: the PasQual study. Proceedings of Eurogin 2010 Conference; 17-20 Feb 2010, Monte Carlo, Monaco, 2010.
40. Drolet M, Brisson M, Maunsell E, et al. Loss of quality of life associated with genital warts: a prospective 6-month study. Proceedings of Eurogin 2010 Conference; 17-20 Feb 2010, Monte Carlo, Monaco, 2010.
41. Department of Health 2010-2011 National Tariff Information. London: Department of Health. http://data.gov.uk/dataset/payment-by-results-2010-11- national-tariff-information (accessed Aug 2010).